Seagen Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · WA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $1.96B | $1.57B | $2.18B | $916.7M | $654.7M | $482.3M |
| Operating income | −$613.0M | −$682.1M | $596.9M | −$220.5M | −$260.0M | −$195.8M |
| Net income | −$610.3M | −$674.5M | $613.7M | −$158.7M | −$222.7M | −$60.0M |
| Total assets | $3.67B | $3.72B | $4.00B | $2.21B | $1.50B | $877.9M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $2.80B | $3.07B | $3.49B | $1.88B | $1.27B | $677.6M |
| EPS (diluted) | $-3.30 | $-3.70 | $3.37 | $-0.96 | $-1.41 | $-0.42 |
| Shares out. | 183.6M | 181.2M | 172.3M | 160.6M | 158.0M | 142.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −31.2%
- Net margin
- −31.1%
- Return on equity
- −21.8%
- Return on assets
- −16.6%
- Return on capital (ROCE)
- −21.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $15.27
- Revenue growth (YoY)
- 24.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Accruals / assets
- −4.3%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- TIVDAKSep 20, 2021
- TUKYSAApr 17, 2020
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2023-06-29A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
- Phase 2Active Not Recruitingreadout ~2023-11-01Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- Phase 2Active Not Recruitingreadout ~2024-07-31Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- Phase 3Active Not Recruitingreadout ~2025-09-05A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Phase 3Active Not Recruitingreadout ~2026-01-12Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- Phase 2Active Not Recruitingreadout ~2026-03-20Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
- Phase 2Active Not Recruitingreadout ~2026-03-27A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
- Phase 3Recruitingreadout ~2026-04-03A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsDec 14, 2023
- Other material eventDec 12, 2023
- Results of operationsNov 1, 2023
- Other material eventOct 19, 2023
- Other material eventSep 22, 2023
- Other material eventSep 5, 2023
- Other material eventAug 16, 2023
- Results of operationsAug 2, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.